- Home
- CGEM vs ABUS Comparison
CGEM vs ABUS Comparison
Compare CGEM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- ABUS
- Stock Information
- Founded
- CGEM 2016
- ABUS N/A
- Country
- CGEM United States
- ABUS United States
- Employees
- CGEM N/A
- ABUS N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- CGEM Health Care
- ABUS Health Care
- Exchange
- CGEM Nasdaq
- ABUS Nasdaq
- Market Cap
- CGEM 730.2M
- ABUS 629.1M
- IPO Year
- CGEM 2021
- ABUS N/A
- Fundamental
- Price
- CGEM $10.55
- ABUS $3.32
- Analyst Decision
- CGEM Strong Buy
- ABUS Strong Buy
- Analyst Count
- CGEM 7
- ABUS 4
- Target Price
- CGEM $31.67
- ABUS $5.50
- AVG Volume (30 Days)
- CGEM 551.6K
- ABUS 753.3K
- Earning Date
- CGEM 03-13-2025
- ABUS 02-27-2025
- Dividend Yield
- CGEM N/A
- ABUS N/A
- EPS Growth
- CGEM N/A
- ABUS N/A
- EPS
- CGEM N/A
- ABUS N/A
- Revenue
- CGEM N/A
- ABUS $6,742,000.00
- Revenue This Year
- CGEM N/A
- ABUS N/A
- Revenue Next Year
- CGEM N/A
- ABUS N/A
- P/E Ratio
- CGEM N/A
- ABUS N/A
- Revenue Growth
- CGEM N/A
- ABUS N/A
- 52 Week Low
- CGEM $9.50
- ABUS $2.27
- 52 Week High
- CGEM $30.19
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- CGEM 38.45
- ABUS 49.63
- Support Level
- CGEM $10.14
- ABUS $3.17
- Resistance Level
- CGEM $11.31
- ABUS $3.38
- Average True Range (ATR)
- CGEM 0.64
- ABUS 0.15
- MACD
- CGEM 0.01
- ABUS 0.02
- Stochastic Oscillator
- CGEM 30.11
- ABUS 46.34
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.